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Objective: To prospectively evaluate quality of life (QoL) evolution 
after a classic pulmonary metastasectomy or after an isolated lung 
perfusion (ILuP) metastasectomy.
Methods: QoL was prospectively recorded in 35 consecutive patients 
(27 classic metastasectomy; 8 ILuP) The European Organisation for 
Research and Treatment of Cancer C30 and lung cancer -13 QoL 
Questionnaires were administered before surgery and 1, 3, 6 and 12 
months postoperatively (MPO).
Results: After a classic metastasectomy, a temporary increase in dyspnea 
(1 MPO p = 0.03 3 MPO p = 0.01), coughing (3 MPO p = 0.01), fatigue 
(1 MPO p = 0.01, 3 MPO p = 0.02), thoracic pain (1 MPO, p = 0.02), 
shoulder dysfunction (1 MPO p = 0.03, 3 MPO p = 0.02) as well as an 
impaired physical (1 MPO p = 0.01, 3 MPO p = 0.04) and role function-
ing (1 MPO p = 0.01, 3 MPO p = 0.01) was reported the first 3 months 
after surgery. Six months after surgery, all domains returned to baseline.
After ILuP metastasectomy, all QoL functioning and symptom 
scores, except for coughing complaints (1 MPO p = 0.03, 3 MPO 
p = 0.04) and shoulder dysfunction (1 MPO p = 0.04, 6 MPO p = 
0.04), returned to baseline at 1 month after surgery. No significant 
differences were seen when QoL evolution was compared between 
classic and ILuP metastasectomy with the exception of a higher bur-
den of thoracic pain (6 MPO p = 0.04, 12 MPO p = 0.01), shoulder 
dysfunction (6 MPO p = 0.04, 12 MPO p = 0.02), and dysphagia 
(6 MPO p = 0.04, 12 MPO p = 0.02) 6 and12 months after ILuP.
Conclusions: All QoL domains returned to baseline at 6 months 
after a classic metastasectomy. After ILuP, only increases in cough-
ing and shoulder dysfunction were reported. In comparison classic 
metastasectomy patients, ILuP patients report more thoracic pain, 
shoulder dysfunction, and dysphagia.
Key Words: Quality of life, European Organisation for Research and 
Treatment of Cancer, Quality of Life Questionnaire-C30, QLQ Lung 
Cancer-13, Lung metastases, Pulmonary metastasectomy, Isolated 
lung perfusion.
(J Thorac Oncol. 2012;7: 1567-1573)
Pulmonary metastasectomy has become a standard treat-ment for selected patients with different primary malig-
nancies including colorectal and renal cell carcinoma. Even 
after complete surgical resection of pulmonary metastases, 
many patients develop recurrent disease in the thorax despite 
the use of systemic chemotherapy, the dosage of which is 
limited because of systemic toxicity. Although subsequent 
operations are feasible and good long-term results have been 
reported, sufficient functional lung parenchyma must remain. 
For this reason, new treatment strategies are being explored.
Similar to isolated limb and liver perfusion, isolated 
lung perfusion (ILuP) is a promising surgical technique for the 
delivery of high-dose chemotherapy with minimal systemic 
toxicity. ILuP with high-dose chemotherapy has proven to 
be highly effective in the experimental models of pulmonary 
metastases with a superior survival advantage compared with 
systemic treatment.1–3 Phase I human studies have shown that 
ILuP is technically feasible with low morbidity and without 
compromising the patient’s long-term pulmonary function.4–6
In addition to the impact on morbidity and mortality, 
new techniques in medicine need to be evaluated with regard 
to their effect on a patient’s quality of life (QoL). Limited 
information is available regarding the long-term QoL evolu-
tion of patients who underwent a pulmonary metastasectomy. 
The objective of the present study is to measure long-term QoL 
evolution after pulmonary metastasectomy and to compare 
QoL after ILuP metastasectomy and classic metastasectomy.
PATIENTS AND METHODS
From January 2005 to December 2008, 35 consecu-
tive patients who underwent a pulmonary metastasectomy 
were included in a prospective QoL evaluation. Eight of the 
35 patients underwent isolated lung perfusion (ILuP) with 
melphalan as part of a phase I trial.5 Patients with pulmonary 
metastases from melphalan-sensitive tumors were included in 
the phase I ILuP study if general and specific criteria were 
met. General criteria to perform a procedure were fourfold: 
metastatic disease assessed by radiologic examination was 
resectable, metastatic disease was confined to the lungs, 
patients had adequate pulmonary and cardiac reserve, and no 
comorbid conditions that preclude an operation were present. 
Exclusion criteria were pregnancy or lactation, uncontrol-
lable infectious disease, liver or kidney insufficiency, severe 
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comorbidity, and previous thoracotomy or pleuropulmonary 
disease resulting in obliteration of the pleural space.5 The 
QoL evolution of those patients was prospectively compared 
with that of 27 patients who underwent a classic metastasec-
tomy. Patients of the extension trial with hyperthermic mel-
phalan infusion were not included in the present study.7 To 
obtain a more homogenous group, only patients operated in 
the Antwerp University Hospital, who underwent a pulmonary 
metastasectomy by anterolateral muscle-sparing thoracotomy 
were included. Patients who underwent a metastasectomy by 
video-assisted thoracic surgery or who underwent a synchro-
nous or metachronous hepatic metastasectomy were excluded 
from the analysis. Further exclusion criteria were age younger 
than 18 years, mortality during the 12-month follow-up 
period, and previous thoracic surgery, The QoL and phase 
I ILuP study were approved by the ethics committee of the 
Antwerp University Hospital, and written informed consent 
was obtained from all patients.
QoL was prospectively recorded using the Dutch ver-
sion of the European Organisation for Research and Treat-
ment of Cancer (EORTC) Quality of Life Questionnaire 
(QLQ)-C30 (cancer core questionnaire)8 and the EORTC 
QLQ-Lung Cancer (LC)13 lung cancer-specific questionnaire 
module.9 The EORTC QLQ-C30 is a self-rating questionnaire 
composed of 30 questions/items and incorporates nine multi-
item scales: five functional scales (physical, role, cognitive, 
emotional, and social), three symptom scales (fatigue, pain, 
nausea/vomiting), a global health/QoL scale, and several 
single items assessing additional symptoms (dyspnea, sleep 
disturbance, constipation, and diarrhea). A final item evalu-
ates the perceived economic consequences of the disease.8 
The EORTC QLQ-LC13 is a supplementary questionnaire 
module and contains 13 questions/items assessing lung can-
cer-associated symptoms (cough, hemoptysis, dyspnea, and 
site-specific pain), chemotherapy/radiotherapy-related side 
effects, and pain medication.9 Reliability and validity of the 
EORTC QLQ-C30 and LC-13 questionnaires have been con-
firmed in international cancer studies.8,9 The questionnaires 
were administered 1 day before surgery and at 1, 3, 6, and 12 
months postoperatively (MPO). The questionnaires were sent 
to the patients by mail, accompanied by a letter with general 
information and the aim of the study.
Statistical analysis was performed using statistical soft-
ware (SPSS, version 18.0, Chicago, IL). In accordance with 
procedures recommended by the EORTC, scores were linearly 
converted to a scale ranging from 0 to100 for each patient. 
For the global health/QoL and functional scales, higher scores 
represent a higher level of functioning. For the symptom 
scales, higher scores represent a greater symptom burden.8,9 
Parametric and nonparametric data were reported as mean 
and median, respectively. The Wilcoxon signed rank test was 
used to compare the mean value before and after surgery. A 
Student’s t test was used to compare parametric data between 
groups. The Mann-Whitney U test and the Kruskall-Wallis 
test were performed to compare nonparametric data. The p 
value was considered statistically significant if 0.05 or lower.
Surgical Procedure of Isolated Lung Perfusion
Patients were intubated with a double-lumen endotra-
cheal tube and underwent an antero- or posterolateral thora-
cotomy in a standard fashion. After inspecting the thoracic 
cavity, contraindications for a complete metastasectomy were 
excluded. All nodules were palpated before perfusion, and 
their anatomic localization was documented before perfu-
sion. In case no preoperative histologic diagnosis was present, 
frozen section of one of the tumor nodules was performed to 
obtain pathologic confirmation of metastatic disease. Next, 
the main pulmonary artery and both pulmonary veins were 
isolated. The pericardium was opened to clamp the pulmonary 
artery and veins centrally. The patient was systemically anti-
coagulated. The pulmonary vasculature was clamped proxi-
mally and cannulated and the main bronchus was snared to 
occlude bronchial arterial blood flow. ILuP with melphalan 
was carried out for a period of 30 minutes with the use of a 
perfusion circuit. During the ILuP, the lung was ventilated. 
At the end, air was removed from the lung and pulmonary 
veins by sequentially removing the pulmonary artery cannula, 
repairing the arteriotomy, removing the cannulas from the pul-
monary veins, and removing the pulmonary artery clamp until 
bleeding from the pulmonary veins had vented all the air. The 
venotomies were repaired and the clamps removed, restoring 
blood flow to the lung. After correcting the activated clotting 
time, a complete metastasectomy was performed. Metastases 
were resected with a margin of 5 mm of normal lung tissue. 
Subsequently, a hilar and mediastinal nodal sampling was per-
formed.5 Morbidity, in-hospital mortality, and long-term mor-
tality of ILuP were recently published.5,6
RESULTS
Table 1 outlines patients’ characteristics for the clas-
sic and the ILuP metastasectomy group. Table 2 shows the 
characteristics of the surgical procedure and postoperative 
recovery in the two groups. No significant differences were 
seen in characteristics of patients and surgical procedure when 
the two groups were compared, with the exception of a sig-
nificant smaller diameter of the resected specimen in the ILuP 
group (p = 0.04). Both groups had a comparable response to 
the QoL questionnaire (Table 3). No significant differences in 
response rate were seen when the two groups were compared. 
Regarding response rate, 21 patients (60.0%) responded to 
all five questionnaires, five (14.3%) to four, four (11.4%) to 
three, and five (14.3%) to two of the questionnaires. There 
were no significant clinicopathological and baseline QoL dif-
ferences between patients who responded to all questionnaires 
and those who did not.
Preoperative QoL
In general, most patients had a moderately impaired 
global well being, role, social and emotional functioning at 
baseline. Preoperatively, patients reported a burden of fatigue, 
sleep deprivation, and loss of appetite. No significant differ-
ences of QoL scores at baseline were seen between the classic 
and the ILuP metastasectomy groups. QoL at baseline for both 
metastasectomy groups is shown in Tables 4 and 5.
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QoL Evolution after Metastasectomy
After a classic metastasectomy, patients reported 
a 3-month temporary decrease in physical functioning 
(1 MPO p = 0.01, 3 MPO p = 0.04) and role functioning 
(1 MPO p = 0.01, 3 MPO p = 0.01). A 1-month decrease 
in cognitive functioning (1 MPO p = 0.03) and global 
well being (1 MPO p = 0.02) was observed. Patients 
also reported an increase in dyspnea the first 3 months 
(1 MPO p = 0.03, 3 MPO p = 0.01), in coughing the 
third month after surgery (3 MPO p = 0.01), and fatigue 
the first 3 months (1 MPO p = 0.01, 3 MPO p = 0.02). 
Patients reported thoracic pain (1 MPO p = 0.02, 3 MPO 
p = 0.04) and shoulder dysfunction (1 MPO p = 0.03, 3 
MPO p = 0.02) the first3 months after a classic metas-
tasectomy. Increases in chemotherapy-related side effects 
were only reported in peripheral neuropathy at 3 months 
after surgery (3 MPO p = 0.04). Six months after surgery, 
all domains returned to baseline values, with the exception 
of emotional functioning (which significantly improved 
6 and 12 months after surgery [6 MPO p = 0.02, 12 MPO 
p = 0.01]).
Patients who underwent ILuP metastasectomy reported 
no decreased QoL functioning scores after surgery. Coughing 
complaints increased the first 3 months after surgery (1 MPO 
p = 0.03, 3 MPO p = 0.04). Patients reported significantly 
more shoulder pain the first and sixth month compared with 
baseline (1 MPO p = 0.04, 6 MPO p = 0.04). Patients reported 
no increase in chemotherapy-related side effects.
When the QoL evolution after metastasectomy was 
compared between the two metastasectomy groups, no 
significant differences were seen with exception of a higher 
burden of thoracic pain and shoulder dysfunction 6 and 12 
months after ILuP metastasectomy (thoracic pain 6 MPO 
p = 0.04, 12 MPO p = 0.01, shoulder dysfunction 6 MPO 
p = 0.04, 12MPO p = 0.02). After ILuP metastasectomy, 
significantly more dysphagia was reported at 6 and 12 months 
compared with the classic metastasectomy (6 MPO p = 0.04, 
12 MPO p = 0.02).
TABLE 1. Patients’ Characteristics at Primary Treatment
Classic 
Metastasectomy
ILup 
Metastasectomy p
n 27 8 —
Male/female 15/12 7/1
(87.5%/12.5%)
0.106
Median age at primary 
treatment (yrs) 
57.1 (12.7) 47.5 (20.2) 0.112
Location primary tumor
 Urogenital 7 (25.9%) 1 (12.5%) 0.391
 Extremities 5 (18.5%) 4 (50.0%) 0.155
 Colorectal 10 (37.0%) 3 (37.5%) 0.982
 Other 5 (18.5%) 0 (0%) 0.022
Histology of primary tumor
 Carcinoma 22 (81.5%) 4 (50.0%) 0.155
 Sarcoma 5 (18.5%) 4 (50.0%) 0.155
Primary treatment
 Surgery 26 (96.2%) 8 (100.0%) 0.558
Adjuvant treatment
 None 10 (37.0%) 5 (62.5%) 0.213
 Neoadjuvant chemotherapy 2 (7.4%) 0 (0%) 0.043
 Adjuvant chemotherapy 14 (14.8%) 3 (37.5%) 0.941
 Neoadjuvant radiotherapy 2 (7.4%) 1 (12.5%) 0.543
 Adjuvant radiotherapy 1 (3.7%) 0 (0%) 0.339
ILuP, isolated lung perfusion.
TABLE 2. Patients’ Characteristics at Pulmonary 
Metastasectomy
Classic 
Metastasectomy
Ilup 
Metastasectomy p
n 27 8 —
Median age at pulmonary 
metastasectomy (SD)
60.4 (13.1) 49.8 (20.9) 0.207
Median disease-free interval 
in months (SD)
39.6 (37.2) 27.0 (28.8) 0.388
N status
 N0 24 (88.8%) 8 (100.0%) 0.339
 N1 1 (3.7%) 0 (0%) 0.586
 N2 2 (7.4%) 0 (0%) 0435
Side
 Unilateral 22 (81.5%) 4 (50.0%) 0.078
 Bilateral staged 5 (18.5%) 4 (50.0%)* 0.078
Resection
 Wedge resection 21 (77.7%) 7 (87.5%) 0.560
 Lobectomy 6 (22.2%) 1 (12.5%) 0.560
Number of resected  
specimens
 1–2 17 (62.9%) 3 (37.5%) 0.213
 3–5 5 (18.5%) 3 (37.5%) 0.275
 >5 5 (18.5%) 2 (25.0%) 0.689
Number of metastases
 1–2 20 (74.0%) 5 (62.5%) 0.209
 3–5 4 (14.8%) 2 (25.0%) 0.276
 >5 3 (11.1%) 1 (12.5%) 0.917
Diameter of the specimen 
(mm)
21.3 (9.6) 12.8 (9.6) 0.04
Median duration of  
hospitalization 
in days (sd)
9.0 (4.9) 11.0 (6.6) 0.383
Postoperative morbidity
 None 21 (77.7%) 5 (62.5%) 0.400
 Atrial arrhythmia 1 (3.7%) 0 (0%) 0.594
 Pneumonia 1 (3.7%) 1 (12.5%) 0.361
 Respiratory insufficiency 0 (0%) 1 (12.5%) 0.065
 Persistent air leak 2 (7.4%) 0 (0%) 0.443
 Neuropathy 1 (3.7%) 1 (12.5%) 0361
 Wound hematoma 1 (3.7%) 0 (0%) 0.594
Adjuvant treatment
 None 22 (81.5%) 7 (87.5%) 0.702
 Neoadjuvantchemotherapy 2 (7.4%) 1 (12.5%) 0.663
 Adjuvant chemotherapy 3(11.1%) 0 (0%) 0.832
ILuP, isolated lung perfusion.
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DISCUSSION
Pulmonary metastasectomy is a widely accepted treat-
ment for many patients with pulmonary metastases. Recent 
studies10–16 have shown that despite preoperative selection, the 
long-term survival rate of patients with pulmonary metastases 
who underwent a complete surgical resection is usually below 
50%. One of the reasons for this rather low survival rate is 
poor local control.16 ILuP is evaluated as one of the possible 
combined modality treatment options to improve survival as it 
delivers high-dose chemotherapy to the lungs while minimizing 
systemic toxicity.4–7
Although clinical research focuses on how to better 
identify the patient most likely to benefit from surgery in 
terms of survival, patients and caregivers also need additional 
information on the potential QoL outcomes after surgery. Risk 
of an impaired QoL after surgery is an important consideration 
for many patients when deciding whether to proceed with 
surgery. Therefore, the optimum patient counseling should 
account not only for traditional measures of performance 
as radical clearance with low postoperative morbidity and 
mortality rates, but also for the anticipated residual QoL. 
Although pulmonary metastasectomy is a common thoracic 
surgical procedure, many unanswered questions remain. 
One of them is the evolution of QoL after pulmonary 
metastasectomy. Measurement of QoL requires prospective 
data collection, including baseline information before the 
intervention. The retrospective nature of the data collection 
in follow-up studies precludes information concerning QoL 
in the literature. QoL data after thoracic surgery for lung 
TABLE 3. Response to Quality of Life Questionnaire
Classic 
Metastasectomy
ILup
Metastasectomy p
n 27 8 —
Baseline before surgery 27 (100%) 8 (100%) —
1 mo after surgery 22 (81.5%) 6 (75.0%) 0.698
3 mos after surgery 23 (85.2%) 7 (87.5%) 0.874
6 mos after surgery 22 (81.5%) 5 (62.5%) 0.275
12 mos after surgery 22 (81.5%) 6 (75.0%) 0.698
ILuP, isolated lung perfusion.
TABLE 4.  Mean QoL Functioning Scores at Baseline and after 1, 3, 6, and 12 months as Measured by the European 
Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C308
Mean Baseline 
QoL Scores
Mean QoL Scores after Surgery (p Value *)
1 Mo 3 Mos 6 Mos 12 Mos
Physical functioning
 Classic metastasectomy 83.2 65.8 (p = 0.01) 75.9 (p = 0.04) 82.5 ns 77.6 ns
 ILuP metastasectomy 93.3 72.2 ns 78.1 ns 82.7 ns 87.0 ns
 p value** ns ns ns Ns Ns
Role functioning
 Classic metastasectomy 79.6 49.3 (p = 0.01) 63.1 (p = 0.01) 75.0 ns 80.3 ns
 ILuP metastasectomy 93.7 72.2 ns 76.2 ns 83.3 ns 80.6 ns
 p value** ns ns ns Ns Ns
Emotional functioning
 Classic metastasectomy 70.4 76.9 ns 77.6 ns 86.8 (p = 0.02) 88.6 (p = 0.01)
 ILuP metastasectomy 71.9 86.1ns 78.6 ns 86.7 ns 81.9 ns
 p value** ns ns ns Ns Ns
Cognitive functioning
 Classic metastasectomy 90.1 88.7 (p = 0.03) 88.4 ns 91.7 ns 90.2 ns
 ILuP metastasectomy 79.2 75.0 ns 80.9 ns 66.7 ns 75.0 ns
 p value** ns Ns ns p = 0.03 Ns
Social functioning
 Classic metastasectomy 77.2 63.7 ns 76.8 ns 84.1 ns 84.1 ns
 ILuP metastasectomy 89.6 83.3 ns 80.9 ns 93.3 ns 86.1 ns
 p value** ns Ns ns Ns Ns
Global well being
 Classic metastasectomy 70.4 62.5 (p = 0.02) 63.1 ns 64.4 ns 72.3 ns
 ILuP metastasectomy 72.9 61.1 ns 63.1 ns 86.7 ns 73.6 ns
 p value** ns Ns ns Ns Ns
*p value indicates significance between the baseline value and the score after 1, 3, 6, and 12 months; **p value indicates significance between the classic and ILuP metastasec-
tomy groups.
Ns, not significant—indicates return to baseline values; ns, not significant—indicates no difference between both groups; QoL, quality of life; ILuP, isolated lung perfusion.
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cancer cannot be transmitted to lung metastasectomy patients, 
because the latter often have different preoperative symptoms, 
mostly undergo sublobar resections, and have prolonged 
multisystem oncologic disease. Only one recent publication 
evaluated QoL after 100 pulmonary metastasectomies, using 
a transxiphoid hand-assisted videothoracoscopic technique. 
In this study, most QoL domains recovered within 3 months 
after surgery.18 The objective of the present study was to assess 
TABLE 5.  Mean QoL Symptom Scores at Baseline and after 1, 3, 6, and 12 Months as Measured by the European Organisation 
for Research and Treatment of Cancer Quality of Life Questionnaire-C30 AND Lung Cancer 138,9
Mean Baseline 
QoL Scores
Mean QoL Scores after Surgery (p Value *)
1 Mo 3 Mos 6 Mos 12 Mos
Dyspnea
 ILuP metastasectomy 6.3 16.7 ns 25.0 ns 16.7 ns 23.6 ns
 p value** ns ns ns ns ns
Coughing
 Classic metastasectomy 10.3 14.4 ns 22.5 (p = 0.01) 8.3 ns 10.3 ns
 ILuP metastasectomy 4.2 19.4 (p = 0.03) 19.0 (p = 0.04) 6.7 ns 13.9 ns
 p value** ns ns ns ns ns
Fatigue
 Classic metastasectomy 21.8 41.4 (p = 0.01) 35.7 (p = 0.02) 28.3 ns 24.2 ns
 ILuP metastasectomy 9.7 35.4 ns 25.4 ns 17.8 ns 29.6 ns
 p value** ns ns ns ns ns
Nausea/vomiting
 Classic metastasectomy 3.7 3.8 ns 7.9 ns 8.3 ns 3.8 ns
 IluP metastasectomy 0 0 ns 4.8 ns 3.3 ns 5.6 ns
 p value** ns ns ns ns ns
Loss of appetite
 Classic metastasectomy 13.6 13.6 ns 10.1 ns 9.1 ns 3.0 ns
 ILuP metastasectomy 4.2 16.7 ns 19.1 ns 0 ns 5.6 ns
 p value** ns ns ns ns ns
Sleep deprivation
 Classic metastasectomy 17.3 22.7 ns 15.9 ns 12.1 ns 15.2 ns
 ILuP metastasectomy 8.3 11.1 ns 4.8 ns 0 ns 27.8 ns
 p value** ns ns ns ns ns
Dysphagia
 Classic metastasectomy 5.1 12.1 ns 5.8 ns 0 ns 3.2 ns
 ILuP metastasectomy 0 0 ns 9.5 ns 13.3 ns 22.2 ns
 p value** ns ns ns p = 0.04 p = 0.02
Peripheral neuropathy
 Classic metastasectomy 7.7 7.6 ns 17.4 ns 23.3 (p = 0.04) 7.9 ns
 ILuP metastasectomy 4.2 0 ns 19.0 ns 13.3 ns 27.8 ns
 p value** ns ns ns ns ns
Alopecia
 Classic metastasectomy 5.1 9.1 ns 11.6 ns 8.3 ns 9.5 ns
 ILuP metastasectomy 0 0 ns 0 ns 0 ns 16.7 ns
 p value** ns ns ns ns ns
Thoracic pain
 Classic metastasectomy 3.8 19.7 (p = 0.02) 10.1 ns 6.7 ns 6.3 ns
 ILuP metastasectomy 0 27.8 ns 23.8 ns 20.0 ns 33.3 ns
 p value** ns ns ns p = 0.04 p = 0.01
Shoulder dysfunction
 Classic metastasectomy 3.8 16.7 (p = 0.03) 18.8 (p = 0.02) 5.0 ns 6.3 ns
 ILuP metastasectomy 8.3 38.9 (p = 0.04) 9.5 ns 33.3 (p = 0.04) 16.7 ns
 p value** ns ns ns p = 0.04 p = 0.02
*p value indicates significance between the baseline value and the score after 1, 3, 6, and 12 months; **p value indicates significance between the classic and ILuP metastasectomy groups.
Ns, not significant—indicates return to baseline values; ns, not significant—indicates no difference between both groups; QoL, quality of life; ILuP, isolated lung perfusion.
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pre- and postoperative QoL after pulmonary metastasectomy, 
comparing the classic metastasectomy technique with ILuP 
metastasectomy, which has not been reported before.
Pulmonary metastasectomy is not performed with the 
primary objective of relieving specific symptoms. A patient 
with symptoms attributable to metastases is likely to be 
excluded from surgery. The present study demonstrates that at 
baseline, metastasectomy patients report no significant symp-
toms with the exception of a moderate burden of dyspnea and 
decreased emotional functioning. Although the degree of dys-
pnea is moderate at baseline, classic metastasectomy patients 
reported a significant increase in dyspnea the first 3 months 
after surgery. Besides dyspnea, patients also complained of 
coughing, fatigue, thoracic pain, shoulder dysfunction, as well 
as decrease in physical and role functioning the first 3 months. 
Six months after surgery, all domains, with the exception of 
emotional functioning, returned to baseline where patients 
reported significantly improvements at 6 and 12 months. ILuP 
metastasectomy patients reported no decreased QoL function-
ing scores after surgery. Except for coughing complaints in 
the first 3 months and shoulder dysfunction at 1 and 6 months 
after surgery, ILuP patients reported no significant change in 
their symptoms.
Although not statistically significant, there was a trend 
toward less pronounced symptoms at baseline in ILuP com-
pared with classic metastasectomy patients, probably because 
of patient selection. When the QoL evolution after metastasec-
tomy was compared between the two metastasectomy groups, 
no significant differences were noted, with the exception of 
a higher burden of thoracic pain, shoulder dysfunction, and 
dysphagia 6 and 12 months after ILuP. This difference was 
probably caused by the more extensive surgical procedure. 
Whether the dysphagia is related to the infused chemotherapy 
needs to be further investigated.
The present study has several limitations. A valid and 
reliable measurement of QoL is of utmost importance. In the 
present study, QoL was assessed by the QLQ-C30 and QLQ 
LC-13. The reliability and validity of these EORTC question-
naires have been confirmed in stage III and IV lung cancer 
patients.8,9 It is unknown whether these standardized question-
naires are also applicable to patients who undergo thoracic 
surgery for lung metastases. Patients had different primary 
tumors, which may influence the QoL evolution. It is debatable 
whether it is useful to group metastases from various cancer 
types in the same report. The results of the present study need 
to be interpreted with caution because of the rather limited 
number of patients included in the study, which may induce a 
type II statistical error. Larger multicenter prospective studies 
evaluating the effect of metastasectomy on QoL evolution are 
necessary. One of the outcome measures of the Pulmonary 
Metastasectomy in Colorectal Cancer trial is QoL evolution 
besides overall survival, relapse-free survival, lung function, 
and health economic assessment.19,20 Although, in general, 
80.7% of patients returned the questionnaire after surgery and 
both groups had statistically comparable compliance, some 
patients did not return their questionnaire. Compliance with 
the QoL assessment is important because the failure to return 
the questionnaire may be influenced by the patients’ QoL 
at that particular time point. Compliance can confound the 
results in two ways. First, patients with advanced disease do 
not complete surveys when they become too ill, leaving only 
those in better health to provide data.21 Hence QoL research 
may overestimate QoL in patients with recurrence and thus 
underestimate the impact of disease progression. Second, 
patients who recover exceptionally well sometimes choose to 
skip the questionnaire because they prefer to put the cancer 
experience behind them.22 Consequently, data may underesti-
mate QoL and therefore the extent of recovery from surgery. 
Despite the mentioned limitations, the findings of this study 
offer valuable information in understanding the evolution in 
QoL and in this way may create realistic postoperative objec-
tives for patients undergoing resection of lung metastases.
In conclusion, the present pilot study prospectively 
documents QoL evolution profiles comparing preoperative 
status with deficits and changes at 1, 3, 6, and 12 months 
after pulmonary metastasectomy. During the first 3 months 
after a classic pulmonary metastasectomy, patients reported 
a significant burden of dyspnea, coughing, fatigue, thoracic 
pain, shoulder dysfunction, and physical and role functioning. 
Six months after surgery, all domains returned to baseline, 
with the exception of emotional functioning where patients 
reported significantly improvements at 6 and 12 months. After 
ILuP metastasectomy, patients reported no decreased QoL 
functioning scores. Except for coughing complaints during 
the first 3 months and shoulder dysfunction at 1 and 6 months 
after surgery, ILuP patients reported no significant change in 
their symptoms. When the QoL evolution after metastasec-
tomy was compared between the two groups, no significant 
differences were seen with the exception of a higher burden of 
thoracic pain, shoulder dysfunction, and dysphagia 6 and 12 
months after ILuP.
ACKNOWLEDGMENTS
The authors are grateful to Sarah Balduyck and Annelies 
Masschelin for their help with data management.
REFERENCES
 1. Grootenboers MJ, Heeren J, van Putte BP, et al. Isolated lung perfusion 
for pulmonary metastases, a review and work in progress. Perfusion 
2006;21:267–276.
 2. Van Putte BP, Hendriks JM, Romijn S, De Greef K, Van Schil PE. Toxicity 
and efficacy of isolated lung perfusion with gemcitabine in a rat model of 
pulmonary metastases. Thorac Cardiovasc Surg 2006;54:129–133.
 3. Van Putte BP, Hendriks JM, Romijn S, et al. Isolated lung perfusion 
with gemcitabine in a rat: pharmacokinetics and survival. J Surg Res 
2003;109:118–122.
 4. Van Schil PE, Furrer M, Friedel G. Locoregional therapy. J Thorac Oncol 
2010;5(6 Suppl 2):S151–S154.
 5. Hendriks JM, Grootenboers MJ, Schramel FM, et al. Isolated lung per-
fusion with melphalan for resectable lung metastases: a phase I clinical 
trial. Ann Thorac Surg 2004;78:1919–1926.
 6. Den Hengst W, Van Putte B,Hendriks J, et al. Long-term survival of a 
phase I clinical trial of isolated lung perfusion with melphalan for resect-
able lung metastases. Eur J Cardiothorac Surg2010; 38: 621–627.
 7. Grootenboers MJ, Schramel FM, van Boven WJ, van Putte BP, Hendriks 
JM, Van Schil PE. Re-evaluation of toxicity and long-term follow-up 
of isolated lung perfusion with melphalan in patients with resectable 
pulmonary metastases: a phase I and extension trial. Ann Thorac Surg 
2007;83:1235–1236.
1573Copyright © 2012 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology  •  Volume 7, Number 10, October 2012 Quality of Life Evolution after Pulmonary Metastasectomy
 8. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization 
for Research and Treatment of Cancer QLQ-C30: a quality-of-life instru-
ment for use in international clinical trials in oncology. J Natl Cancer Inst 
1993;85:365–376.
 9. Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M. The EORTC 
QLQ-LC13: a modular supplement to the EORTC Core Quality of Life 
Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC 
Study Group on Quality of Life. Eur J Cancer 1994;30A:635–642.
 10. Smith R, Pak Y, Kraybill W, Kane JM 3rd. Factors associated with actual 
long-term survival following soft tissue sarcoma pulmonary metastasec-
tomy. Eur J Surg Oncol 2009;35:356–361.
 11. Chen F, Miyahara R, Bando T, et al. Prognostic factors of pulmonary 
metastasectomy for osteosarcomas of the extremities. Eur J Cardiothorac 
Surg 2008;34:1235–1239.
 12. Chen F, Fujinaga T, Sato K, et al. Significance of tumor recurrence before 
pulmonary metastasis in pulmonary metastasectomy for soft tissue sar-
coma. Eur J Surg Oncol 2009;35:660–665.
 13. Lee WS, Yun SH, Chun HK, et al. Pulmonary resection for metastases 
from colorectal cancer: prognostic factors and survival. Int J Colorectal 
Dis 2007;22:699–704.
 14. Joosten J, Bertholet J, Keemers-Gels M, Barendregt W, Ruers T. 
Pulmonary resection of colorectal metastases in patients with or with-
out a history of hepatic metastases. Eur J Surg Oncol 2008;34:895–899.
 15. Welter S, Jacobs J, Krbek T, Krebs B, Stamatis G. Long-term survival 
after repeated resection of pulmonary metastases from colorectal cancer. 
Ann Thorac Surg 2007;84:203–210.
 16. Watanabe K, Nagai K, Kobayashi A, Sugito M, Saito N. Factors influ-
encing survival after complete resection of pulmonary metastases from 
colorectal cancer. Br J Surg 2009;96:1058–1065.
 17. The International Registry of Lung Metastases. Long-term results of 
lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac 
Cardiovasc Surg 1997; 113:37–49.
 18. Mineo TC, Ambrogi V, Mineo D, Pompeo E. Transxiphoid hand-assisted 
videothoracoscopic surgery. Ann Thorac Surg 2007;83:1978–1984.
 19. Treasure T, Fallowfield L, Lees B, Farewell V. Pulmonary metasta-
sectomy in colorectal cancer: the PulMiCC trial. Thorax 2012;67: 
185–187.
 20. Treasure T, Fallowfield L, Farewell V, et al.; Pulmonary Metastasectomy in 
Colorectal Cancer (PulMiCC) trial development group. Pulmonary metas-
tasectomy in colorectal cancer: time for a trial. Eur J Surg Oncol 2009; 
35:686–689.
 21. Fairclough D. Design and analysis of quality of life studies. In clinical 
trials. Boca Raton FL Capman & Hall / CRC 2002;69–72.
 22. Bernhard J, Cella DF, Coates AS, et al. Missing quality of life data in 
cancer clinical trials: serious problems and challenges. Stat Med 1998; 
17:517–532.
